Titre : Méthode en double aveugle

Méthode en double aveugle : Questions médicales fréquentes

Termes MeSH sélectionnés :

Radiotherapy, Intensity-Modulated

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la méthode en double aveugle aide-t-elle au diagnostic ?

Elle permet d'évaluer l'efficacité d'un traitement sans biais d'observation.
Méthodes de recherche Biais Évaluation clinique
#2

Quels tests utilisent la méthode en double aveugle ?

Des essais cliniques pour tester des médicaments ou des interventions.
Essais cliniques Médicaments Interventions thérapeutiques

Symptômes 2

#1

Les symptômes sont-ils évalués en double aveugle ?

Oui, cela permet d'éviter que les attentes influencent les rapports de symptômes.
Symptômes Évaluation des symptômes Biais d'observation
#2

Comment les symptômes sont-ils mesurés en double aveugle ?

Par des échelles standardisées, sans que les évaluateurs sachent le traitement reçu.
Échelles d'évaluation Mesure des symptômes Évaluation clinique

Prévention 2

#1

La méthode en double aveugle est-elle utilisée en prévention ?

Oui, pour évaluer l'efficacité des vaccins ou des interventions préventives.
Prévention Vaccins Essais cliniques
#2

Comment la prévention est-elle testée en double aveugle ?

En comparant un groupe recevant le traitement préventif à un groupe placebo.
Interventions préventives Placebo Essais contrôlés

Traitements 2

#1

Quels traitements utilisent souvent la méthode en double aveugle ?

Les essais de nouveaux médicaments, thérapies ou interventions chirurgicales.
Traitements médicaux Essais cliniques Interventions chirurgicales
#2

Pourquoi utiliser la méthode en double aveugle pour les traitements ?

Pour garantir que les résultats ne soient pas influencés par des attentes ou des biais.
Biais Efficacité des traitements Essais contrôlés

Complications 2

#1

Les complications sont-elles prises en compte en double aveugle ?

Oui, pour évaluer les effets indésirables des traitements sans biais.
Complications Effets indésirables Évaluation clinique
#2

Comment les complications sont-elles rapportées ?

Par des rapports standardisés, sans que les évaluateurs sachent le traitement reçu.
Rapports d'effets indésirables Évaluation des complications Essais cliniques

Facteurs de risque 2

#1

La méthode en double aveugle évalue-t-elle les facteurs de risque ?

Indirectement, en contrôlant les variables pour isoler l'effet du traitement.
Facteurs de risque Contrôle des variables Essais cliniques
#2

Comment les facteurs de risque sont-ils pris en compte ?

En randomisant les participants pour équilibrer les caractéristiques entre groupes.
Randomisation Caractéristiques des participants Essais contrôlés
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Méthode en double aveugle : Questions médicales les plus fréquentes", "headline": "Méthode en double aveugle : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Méthode en double aveugle : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-13", "dateModified": "2025-04-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Méthode en double aveugle" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Méthodologie en recherche épidémiologique", "url": "https://questionsmedicales.fr/mesh/D015340", "about": { "@type": "MedicalCondition", "name": "Méthodologie en recherche épidémiologique", "code": { "@type": "MedicalCode", "code": "D015340", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N06.850.520.445" } } }, "about": { "@type": "MedicalCondition", "name": "Méthode en double aveugle", "alternateName": "Double-Blind Method", "code": { "@type": "MedicalCode", "code": "D004311", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Hiroyoshi Yajima", "url": "https://questionsmedicales.fr/author/Hiroyoshi%20Yajima", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Miho Takayama", "url": "https://questionsmedicales.fr/author/Miho%20Takayama", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Judith M Schlaeger", "url": "https://questionsmedicales.fr/author/Judith%20M%20Schlaeger", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Nobuari Takakura", "url": "https://questionsmedicales.fr/author/Nobuari%20Takakura", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Ted J Kaptchuk", "url": "https://questionsmedicales.fr/author/Ted%20J%20Kaptchuk", "affiliation": { "@type": "Organization", "name": "Program in Placebo Studies, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.", "datePublished": "2024-05-27", "url": "https://questionsmedicales.fr/article/38802765", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12885-024-12383-7" } }, { "@type": "ScholarlyArticle", "name": "Online adaptive planning methods for intensity-modulated radiotherapy.", "datePublished": "2023-05-11", "url": "https://questionsmedicales.fr/article/37068488", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1088/1361-6560/accdb2" } }, { "@type": "ScholarlyArticle", "name": "Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.", "datePublished": "2023-07-06", "url": "https://questionsmedicales.fr/article/37423227", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S1470-2045(23)00265-6" } }, { "@type": "ScholarlyArticle", "name": "Racial and Ethnic Health Disparities in Delay to Initiation of Intensity-Modulated Radiotherapy.", "datePublished": "2022-08-05", "url": "https://questionsmedicales.fr/article/35930751", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1200/OP.22.00104" } }, { "@type": "ScholarlyArticle", "name": "Comparative Study of Dysphagia-optimized Intensity Modulated Radiotherapy (Do-IMRT) and Standard Intensity Modulated Radiotherapy (S-IMRT) and Its Clinical Correlation in Head and Neck Cancer Patients.", "datePublished": "2023-11-01", "url": "https://questionsmedicales.fr/article/38019227", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.31557/APJCP.2023.24.11.3697" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Environnement et santé publique", "item": "https://questionsmedicales.fr/mesh/D004778" }, { "@type": "ListItem", "position": 3, "name": "Santé publique", "item": "https://questionsmedicales.fr/mesh/D011634" }, { "@type": "ListItem", "position": 4, "name": "Méthodes épidémiologiques", "item": "https://questionsmedicales.fr/mesh/D004812" }, { "@type": "ListItem", "position": 5, "name": "Méthodologie en recherche épidémiologique", "item": "https://questionsmedicales.fr/mesh/D015340" }, { "@type": "ListItem", "position": 6, "name": "Méthode en double aveugle", "item": "https://questionsmedicales.fr/mesh/D004311" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Méthode en double aveugle - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Méthode en double aveugle", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Méthode en double aveugle", "description": "Comment la méthode en double aveugle aide-t-elle au diagnostic ?\nQuels tests utilisent la méthode en double aveugle ?", "url": "https://questionsmedicales.fr/mesh/D004311?mesh_terms=Radiotherapy,+Intensity-Modulated#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Méthode en double aveugle", "description": "Les symptômes sont-ils évalués en double aveugle ?\nComment les symptômes sont-ils mesurés en double aveugle ?", "url": "https://questionsmedicales.fr/mesh/D004311?mesh_terms=Radiotherapy,+Intensity-Modulated#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Méthode en double aveugle", "description": "La méthode en double aveugle est-elle utilisée en prévention ?\nComment la prévention est-elle testée en double aveugle ?", "url": "https://questionsmedicales.fr/mesh/D004311?mesh_terms=Radiotherapy,+Intensity-Modulated#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Méthode en double aveugle", "description": "Quels traitements utilisent souvent la méthode en double aveugle ?\nPourquoi utiliser la méthode en double aveugle pour les traitements ?", "url": "https://questionsmedicales.fr/mesh/D004311?mesh_terms=Radiotherapy,+Intensity-Modulated#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Méthode en double aveugle", "description": "Les complications sont-elles prises en compte en double aveugle ?\nComment les complications sont-elles rapportées ?", "url": "https://questionsmedicales.fr/mesh/D004311?mesh_terms=Radiotherapy,+Intensity-Modulated#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Méthode en double aveugle", "description": "La méthode en double aveugle évalue-t-elle les facteurs de risque ?\nComment les facteurs de risque sont-ils pris en compte ?", "url": "https://questionsmedicales.fr/mesh/D004311?mesh_terms=Radiotherapy,+Intensity-Modulated#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la méthode en double aveugle aide-t-elle au diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'évaluer l'efficacité d'un traitement sans biais d'observation." } }, { "@type": "Question", "name": "Quels tests utilisent la méthode en double aveugle ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques pour tester des médicaments ou des interventions." } }, { "@type": "Question", "name": "Les symptômes sont-ils évalués en double aveugle ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, cela permet d'éviter que les attentes influencent les rapports de symptômes." } }, { "@type": "Question", "name": "Comment les symptômes sont-ils mesurés en double aveugle ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Par des échelles standardisées, sans que les évaluateurs sachent le traitement reçu." } }, { "@type": "Question", "name": "La méthode en double aveugle est-elle utilisée en prévention ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, pour évaluer l'efficacité des vaccins ou des interventions préventives." } }, { "@type": "Question", "name": "Comment la prévention est-elle testée en double aveugle ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "En comparant un groupe recevant le traitement préventif à un groupe placebo." } }, { "@type": "Question", "name": "Quels traitements utilisent souvent la méthode en double aveugle ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les essais de nouveaux médicaments, thérapies ou interventions chirurgicales." } }, { "@type": "Question", "name": "Pourquoi utiliser la méthode en double aveugle pour les traitements ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Pour garantir que les résultats ne soient pas influencés par des attentes ou des biais." } }, { "@type": "Question", "name": "Les complications sont-elles prises en compte en double aveugle ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, pour évaluer les effets indésirables des traitements sans biais." } }, { "@type": "Question", "name": "Comment les complications sont-elles rapportées ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Par des rapports standardisés, sans que les évaluateurs sachent le traitement reçu." } }, { "@type": "Question", "name": "La méthode en double aveugle évalue-t-elle les facteurs de risque ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Indirectement, en contrôlant les variables pour isoler l'effet du traitement." } }, { "@type": "Question", "name": "Comment les facteurs de risque sont-ils pris en compte ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "En randomisant les participants pour équilibrer les caractéristiques entre groupes." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 08/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Hiroyoshi Yajima

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Miho Takayama

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Judith M Schlaeger

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Nobuari Takakura

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Ted J Kaptchuk

2 publications dans cette catégorie

Affiliations :
  • Program in Placebo Studies, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA.
  • Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Publications dans "Méthode en double aveugle" :

Booil Jo

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry and Behavioral Science, Stanford University, Stanford, CA, USA.
Publications dans "Méthode en double aveugle" :

Cody A Cushing

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Hakwan Lau

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Mitsuo Kawato

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Michelle G Craske

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Vincent Taschereau-Dumouchel

2 publications dans cette catégorie

Publications dans "Méthode en double aveugle" :

Guus A M Kortman

2 publications dans cette catégorie

Affiliations :
  • NIZO Food Research B.V., 6718 ZB Ede, The Netherlands.

Maartje van den Belt

2 publications dans cette catégorie

Affiliations :
  • NIZO Food Research B.V., 6718 ZB Ede, The Netherlands.

Xuan Zhang

2 publications dans cette catégorie

Affiliations :
  • Chinese EQUATOR Centre, Hong Kong Chinese Medicine Clinical Study Centre, Chinese Clinical Trial Registry (Hong Kong), School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong, People's Republic of China.

Yernar Dauletovich Mamyrov

1 publication dans cette catégorie

Affiliations :
  • Department of Emergency Medicine, Pavlodar Branch of NCJSC Semey Medical University, Pavlodar, Kazakhstan.
Publications dans "Méthode en double aveugle" :

Daulet Urazovich Mamyrov

1 publication dans cette catégorie

Affiliations :
  • Department of Emergency Medicine, Pavlodar Branch of NCJSC Semey Medical University, Pavlodar, Kazakhstan.
Publications dans "Méthode en double aveugle" :

Gulzhanat Ertaevna Jakova

1 publication dans cette catégorie

Affiliations :
  • Department of Surgery, Pavlodar Branch of NCJSC Semey Medical University, Pavlodar, Kazakhstan.
Publications dans "Méthode en double aveugle" :

Yoshihiro Noso

1 publication dans cette catégorie

Affiliations :
  • Department of Health Services Management, Hiroshima International University, Hiroshima, Japan.
Publications dans "Méthode en double aveugle" :

Marat Kelisovich Syzdykbayev

1 publication dans cette catégorie

Affiliations :
  • Department of Surgery, Anesthesiology and Reanimatology, Semey Medical University, Semey, Kazakhstan.
Publications dans "Méthode en double aveugle" :

Tony Bazi

1 publication dans cette catégorie

Affiliations :
  • American University of Beirut, Beirut, Lebanon. tb14@aub.edu.lb.
Publications dans "Méthode en double aveugle" :

Sources (10000 au total)

Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.

Radiotherapy interruption (RTI) prolongs the overall total treatment time and leads to local control loss in many cancers, but it is unclear in esophageal cancer. We aimed to evaluate the influence of... A total of 299 patients with esophageal squamous cell carcinoma from 2017 to 2019 were retrospectively analyzed to investigate the effect of RTI on OS, PFS, and LRFS. The delayed time of radiotherapy ... The 3-year OS, PFS, and LRFS rates were 53.0%, 42.0%, and 48.0%, respectively. The univariate and multivariate analyses showed that the delayed time > 3 days was an independent adverse prognostic fact... There was a significant correlation between delayed time and local control of esophageal cancer. The delayed time for more than 3 days might decrease the survival outcome, and increase the local recur...

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.

Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with chemoradiotherapy with curative intent but at the consequence of adverse effects on quality of life. We aimed to investig... DARS was a parallel-group, phase 3, multicentre, randomised, controlled trial done in 22 radiotherapy centres in Ireland and the UK. Participants were aged 18 years and older, had T1-4, N0-3, M0 oroph... From June 24, 2016, to April 27, 2018, 118 patients were registered, 112 of whom were randomly assigned (56 to each treatment group). 22 (20%) participants were female and 90 (80%) were male; median a... Our findings suggest that DO-IMRT improves patient-reported swallowing function compared with standard IMRT. DO-IMRT should be considered a new standard of care for patients receiving radiotherapy for... Cancer Research UK....

Racial and Ethnic Health Disparities in Delay to Initiation of Intensity-Modulated Radiotherapy.

Delays in initiation of radiotherapy may contribute to inferior oncologic outcomes that are more commonly observed in minoritized populations in the United States. We aimed to examine inequities assoc... The National Cancer Database was queried to identify the 10 cancer sites most commonly treated with IMRT. Interval to initiation of treatment (IIT) was broken into quartiles for each disease site, wit... Among patients (n = 350,425) treated with IMRT between 2004 and 2017, non-Hispanic Black (NHB), Hispanic, and Asian patients were significantly more likely to have delayed IIT with IMRT for nearly all... Delays in initiation of IMRT in NHB, Hispanic, and Asian patients may contribute to the known differences in cancer outcomes and warrant further investigation, particularly to further clarify the role...

Comparative Study of Dysphagia-optimized Intensity Modulated Radiotherapy (Do-IMRT) and Standard Intensity Modulated Radiotherapy (S-IMRT) and Its Clinical Correlation in Head and Neck Cancer Patients.

Dosimetric sparing of critical swallowing structures like constrictor muscles and larynx can lead to improved functional outcomes in head and neck cancer patients treated by chemoradiation.... A total of 50 Patients with newly diagnosed, biopsy proven AJCC stage II-IV head and neck squamous cell cancers (HNSCC) were prospectively studied. 25 patients were randomized in each arm of Dysphagia... Patients in both arms showed significant (P <0.01 or P < 0.001) improvement in MDADI (global and composite), UW-QOL and Water Swallow Test scores. However, the improvements were found significantly hi... The Do-IMRT improves swallowing functions compared to S-IMRT in HNSCC patients treated with radical chemoradiation....

Concurrent chemoradiotherapy versus radiotherapy alone for stage II nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.

Concurrent chemoradiotherapy has long been a standardized therapy for localized advanced nasopharyngeal cancer. It is widely used in clinical applications. In contrast, NCCN guidelines highlight that ... We searched the relevant literature in PubMed, EMBASE, and Cochrane, extracting relevant data from the searched literature. The main items extracted were hazard ratios (HRs), risk ratios (RRs) and 95%... Our study included seven articles involving 1633 cases of stage II nasopharyngeal cancer. The survival outcomes were overall survival (OS) (HR = 1.03, 95% CI (0.71-1.49), P = 0.87), progression-free s... In the era of intensity-modulated radiotherapy, concurrent chemoradiotherapy and radiotherapy alone have the same survival benefits, and concurrent chemoradiotherapy increases acute hematological toxi...

Is there a dosimetric advantage of volumetric modulated arc therapy over intensity modulated radiotherapy in head and neck cancer?

A planning study was performed to evaluate dosimetric differences between intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for head and neck cancer (HNC) for se... 30 patients with HNC were included, 15 treated with SIB and 15 with Seq-Boost. For all patients both VMAT and IMRT plans were completed. The planning objective for PTV was 95% of dose covering minimum... Both techniques achieved the set objectives regarding PTV coverage and organ sparing. SIB plans presented a statistically significant better homogeneity for VMAT (p = 0.0096), while Seq-boost showed a... VMAT shows dosimetric superiority to IMRT in some cases, however an adequate coverage of the target volumes and a suitable OAR sparing can be achieved with both techniques. Though IMRT is still the st...

Favorable outcome in advanced pheochromocytoma and paraganglioma after hypofractionated intensity modulated radiotherapy.

The purpose of this study was to review outcomes of patients with advanced/metastatic pheochromocytoma/paraganglioma (PPGL) treated at our institution with Intensity-modulated radiotherapy (IMRT), des... A retrospective study on patients with advanced/metastatic PPGL who received IMRT at Peking Union Medical College Hospital between 2014 and 2019. A total of 14 patients with 17 lesions were included i... OS at 2 years was 78% for all patients. For lesions evaluated by RECIST response, at least stable disease of the target lesion was achieved in 94% and distant progression in 28.5%, with an average tim... We have found hypofractionated IMRT effective as an additional therapy for patients with advanced primary tumors or recurrence in situ and not amenable to complete surgical resection....

Intensity-modulated radiotherapy for cushing's disease: single-center experience in 70 patients.

Intensity-modulated radiotherapy (IMRT) is a modern precision radiotherapy technique for the treatment of the pituitary adenoma.... Aim to investigate the efficacy and toxicity of IMRT in treating Cushing's Disease (CD).... 70 of 115 patients with CD treated with IMRT at our institute from April 2012 to August 2021 were included in the study. The radiation doses were usually 45-50 Gy in 25 fractions. After IMRT, endocrin... At a median follow-up time of 36.8 months, the endocrine remission rate at 1, 2, 3 and 5 years were 28.5%, 50.2%, 62.5% and 74.0%, respectively. The median time to remission was 24 months (95%CI: 14.0... IMRT was a highly effective second-line therapy with low side effect profile for CD patients. Endocrine remission, tumor control and recurrence rates were comparable to previous reports on FRT and SRS...

Patterns and prognosis of regional recurrence in nasopharyngeal carcinoma after intensity-modulated radiotherapy.

We analyzed the patterns of lymph node (LN) failure and prognosis in patients with regional recurrent nasopharyngeal carcinoma (rNPC) alone after primary intensity-modulated radiotherapy (IMRT).... A total of 175 patients who were treated with IMRT between 2010 and 2015 and who experienced regional recurrence alone were included. Recurrent LNs were re-located in the initial pretreatment imaging ... Level IIb (49.1%, 86/175) was the most frequent recurrence site, followed by level IIa (36%), level III (18.9%), level IVa (12%), the retropharyngeal region (8%), level Va (6.9%), and the parotid regi... In-field failure represented the main pattern of regional recurrence and out-field failure mainly occurred in the parotid gland and level Ib. Patients with regional rNPC alone had a good prognosis aft...